1 Green Flag for AbbVie (ABBV) Stock Right Now

Key Points

• AbbVie is a compelling pharmaceutical company with scores of drugs and treatments in development.

• It's long been a solid dividend payer and grower, too.

• Its stock isn't cheap right now, so think twice before investing -- or perhaps build a position over time.

• 10 stocks we like better than AbbVie ›

AbbVie (NYSE: ABBV) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the company is its dividend. AbbVie's recent dividend yield was a solid 3.1% -- the S&P 500's recent yield was a mere 1.2% -- and better still, it has been growing, with plenty of room to keep doing so.

Over the past five years, AbbVie hiked its payout by an average annual rate of 7%. The total annual payout was recently around $6.56 per share, which is up from $5.20 in 2021 and $3.59 in 2018. Clearly, there's been a lot of growth!

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

AbbVie's payout ratio -- the percentage of earnings paid out in dividends -- is quite reasonable, too, at less than 50%. That leaves plenty of room for further increases.

Like other pharmaceutical companies, AbbVie has faced the loss of patent protection for various drugs over time, most notably for its blockbuster Humira. But that was never a surprise, and AbbVie has around 90 treatments in its pipeline, having invested nearly $11 billion in research and development in 2024 alone. The majority of those treatments are in the mid to late stages of development.

AbbVie's stock has averaged annual gains of 15.8% over the past decade, and its future is quite promising. But with a forward-looking price-to-earnings (P/E) ratio of 15 at the moment (well above the five-year average near 12), shares aren't a screaming bargain. You might want to wait and hope for a lower price -- or just buy into the stock gradually over time.

Should you invest $1,000 in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $649,037!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,086,028!*

Now, it’s worth noting Stock Advisor’s total average return is 1,056% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 8, 2025

Selena Maranjian has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.